EUVIMEDEUVIMED entdecken
Crossref

Efficacy and tolerability of calcipotriol combined with microneedling in patients with vitiligo: a pilot prospective study

Daryia Kairesheva, Nader Ouaili, Vadim V. Pyatenko, Konstantin M. Lomonosov

Russian Journal of Skin and Venereal Diseases · 06.04.2026 · 29 (3) · 265-271

DOI: 10.17816/dv701953 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Russian Journal of Skin and Venereal Diseases, online erschienen am 06.04.2026. Verfasst von Daryia Kairesheva und 3 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vitiligo is a chronic dermatosis characterized by depigmented patches, with a considerable impact on the patient’s psychoemotional state. Given the growing prevalence of vitiligo, the need for well-tolerated and effective combination therapies remains relevant. AIM: The work aimed to assess the efficacy and tolerability of calcipotriol combined with microneedling in patients with stable non-segmental vitiligo. METHODS: A single-center, pilot, prospective experimental study included 15 patients (9 women and 6 men; mean age: 18–60 years) with stable non-segmental vitiligo. All patients had microneedling once weekly, followed by daily application of calcipotriol throughout the treatment period. The study lasted 16 weeks (12 weeks of therapy and 4 weeks of follow-up). The following outcome assessments were used: Vitiligo Area Scoring Index (VASI), visual analog repigmentation scale (G0–G4), Dermatology Life Quality Index (DLQI), and numeric rating scale (NRS, 0–10 points) for pain. RESULTS: After 12 weeks of therapy, VASI improved by 44.4% (Wilcoxon signed-rank test, p 0.05), and 86.7% of patients achieved repigmentation of 25%. Mild adverse events (primarily transient erythema, pruritus, and pain) were reported in 73.3% of patients. There were no serious adverse reactions, and none of the patients discontinued treatment. Pain during procedures was mild (median NRS score 2.0). There was a significant improvement in quality of life, with a 4-point reduction in DLQI (40%; р 0.05). CONCLUSION: Calcipotriol combined with microneedling is effective and well-tolerated in patients with stable non-segmental vitiligo, with a considerable improvement in quality of life.

Zitieren

APA

Kairesheva, D., Ouaili, N., Pyatenko, V. V., & Lomonosov, K. M. (2026). Efficacy and tolerability of calcipotriol combined with microneedling in patients with vitiligo: a pilot prospective study. Russian Journal of Skin and Venereal Diseases, 29(3), 265-271. https://doi.org/10.17816/dv701953

Vancouver

Kairesheva D, Ouaili N, Pyatenko VV, Lomonosov KM. Efficacy and tolerability of calcipotriol combined with microneedling in patients with vitiligo: a pilot prospective study. Russian Journal of Skin and Venereal Diseases. 2026;29(3):265-271. doi:10.17816/dv701953

BibTeX
@article{Kairesheva2026,
  author = {Kairesheva, Daryia and Ouaili, Nader and Pyatenko, Vadim V. and Lomonosov, Konstantin M.},
  title = {Efficacy and tolerability of calcipotriol combined with microneedling in patients with vitiligo: a pilot prospective study},
  journal = {Russian Journal of Skin and Venereal Diseases},
  year = {2026},
  volume = {29},
  number = {3},
  pages = {265--271},
  doi = {10.17816/dv701953}
}
Kostenlos starten →